Biosimilars were introduced with the promise of expanding access to biologic therapies while reducing healthcare costs. As more blockbuster biologics lose exclusivity, biosimilars are becoming an incr...
For decades, women’s health remained one of the most underfunded and underserved areas in healthcare despite representing half the global population. Many conditions affecting women received limited r...
Contract development and manufacturing organizations, often referred to as CDMOs, were once viewed primarily as outsourced service providers supporting pharmaceutical production. Today, their role is ...
As the pharmaceutical industry becomes increasingly digital, cybersecurity is emerging as one of the sector’s most urgent and underestimated risks. Clinical trials, manufacturing operations, supply ch...
The COVID-19 pandemic fundamentally transformed the global vaccine industry, accelerating scientific innovation, manufacturing investment, and public awareness at an unprecedented pace. Technologies t...
Rare diseases were once considered commercially unattractive due to their limited patient populations and high development costs. Today, however, they have become one of the fastest growing areas of i...
Sustainability in the pharmaceutical industry is evolving beyond environmental, social, and governance reporting into a broader strategic priority. What was once viewed primarily as a corporate respon...
Healthcare is entering an era where data may become as strategically valuable as the therapies themselves. From clinical trials and wearable devices to electronic health records and genomic sequencing...
The Obesity Drug Gold Rush: Healthcare Breakthrough or Market Frenzy? The global pharmaceutical industry is witnessing an unprecedented surge in demand for obesity therapies, transforming what was onc...
The pharmaceutical industry is once again approaching a major patent cliff, with several blockbuster therapies set to lose exclusivity over the next few years. For many companies, these products have ...
